Related MeSH Hierarchy (7)
Diseases [C] » Neoplasms [C04] » Neoplasms by Histologic Type » Neoplasms, Glandular and Epithelial » Carcinoma » Carcinoma, Squamous Cell » Esophageal Squamous Cell Carcinoma
Diseases [C] » Neoplasms [C04] » Neoplasms by Histologic Type » Neoplasms, Glandular and Epithelial » Neoplasms, Squamous Cell » Carcinoma, Squamous Cell » Esophageal Squamous Cell Carcinoma
Diseases [C] » Neoplasms [C04] » Neoplasms by Site » Digestive System Neoplasms » Gastrointestinal Neoplasms » Esophageal Neoplasms » Esophageal Squamous Cell Carcinoma
Diseases [C] » Neoplasms [C04] » Neoplasms by Site » Head and Neck Neoplasms » Esophageal Neoplasms » Esophageal Squamous Cell Carcinoma
Diseases [C] » Digestive System Diseases [C06] » Digestive System Neoplasms » Gastrointestinal Neoplasms » Esophageal Neoplasms » Esophageal Squamous Cell Carcinoma
Diseases [C] » Digestive System Diseases [C06] » Gastrointestinal Diseases » Esophageal Diseases » Esophageal Neoplasms » Esophageal Squamous Cell Carcinoma
Diseases [C] » Digestive System Diseases [C06] » Gastrointestinal Diseases » Gastrointestinal Neoplasms » Esophageal Neoplasms » Esophageal Squamous Cell Carcinoma
Description
A carcinoma that originates usually from cells on the surface of the middle and lower third of the ESOPHAGUS. Tumor cells exhibit typical squamous morphology and form large polypoid lesions. Mutations in RNF6, LZTS1, TGFBR2, DEC1, and WWOX1 genes are associated with this cancer. MeSH
Hierarchy View
Phase 4 Indicated Drugs (1)
Phase 3 Indicated Drugs (21)
Phase 2 Indicated Drugs (42)
Phase 1 Indicated Drugs (17)
Other Experimental Indicated Drugs (3)
Organization Involved with Phase 4 Indications (1)
Organization Involved with Phase 3 Indications (58)
Biotech Pharmaceutical Co., Ltd.
Chinese Academy of Medical Sciences
Huai'an First People's Hospital
Huai'an Second People's Hospital
Huazhong University of Science and Technology
Innovent Biologics (Suzhou) Co. Ltd.
Jiangxi Provincial Cancer Hospital
National Cancer Institute (NCI)
People's Liberation Army of China
Organization Involved with Phase 2 Indications (68)
Anhui College of Traditional Chinese Medicine
Blokhin's Russian Cancer Research Center
China Three Gorges University, Yichang, China
City of Hope National Medical Center
ECOG-ACRIN Cancer Research Group
IKF Klinische Krebsforschung GmbH am Krankenhaus Nordwest
Instituto do Cancer do Estado de São Paulo
Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
Nang Kuang Pharmaceutical Co., Ltd.
National Cancer Institute, France
National Cheng Kung University
Royal Marsden Hospital NHS Trust
Russian Academy of Medical Sciences
Shantou University Medical College
Organization Involved with Phase 1 Indications (8)
Organization Involved with Other Experimental Indications (20)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
